Herpes Simplex Virus (HSV) Vaccines Market Top Companies Trends, Product Innovations, Technology and Revenue Status: CMI

Herpes simplex virus (HSV) causes herpes infection. This virus is majorly found in genitals or mouth and also found on various body parts. There are two types of herpes simplex virus such as type 1 (HSV-1) and type 2 (HSV-2), in which HSV-1 is oral herpes that cause sores around lips and mouth (fever blisters or cold sores), while HSV-2 is genital herpes, wherein sores are found around genitals and rectum. HSV-1 is very common and extremely contagious infection, and HSV-1 infections occurring around mouth are known as oral-labial, or oral-facial herpes. A very few cases of genital herpes (infections occur in genital or anal area) are found in HSV-1. Herpes simplex virus (HSV-2) is most common sexually transmitted virus causing genital herpes (GH) and is highly contagious infection. HSV-2 infection is long lasting and incurable. There is more risk for patients suffering from HSV-2 of acquiring human immunodeficiency virus (HIV) infection. Probability of reoccurrence of HSV-1 is less frequent compared to HSV-2.

Request to view Sample Report: https://www.coherentmarketinsights.com/insight/request-sample/2845

Global Herpes Simplex Virus (HSV) Vaccines Market Drivers

Factors such as extensive research and development is expected to drive global herpes simplex virus (HSV) vaccines market growth over the forecast period. Leading players in the market such as GlaxoSmithKline (GSK), Sanofi SA, and others have HSV vaccines in the development phases. GSK’s vaccine SB208141 completed phase III studies in 2009, which started in 2003. GSK carried out several other clinical trial studies on the same vaccine, considering various different parameters and formulations (with or without monophosphoryl lipid adjuvant [MPL]). Sanofi Pasteur has vaccine HSV529 for HSV-2 in phase I, whose clinical trial study started in 2015 and completed in 2018. Moreover, Vical, Inc. has VCL-HB01, whose phase I study started in September 2016, and completed in December 2018. Furthermore, Genocea Biosciences, Inc. vaccine GEN-003 is in phase II study where the study started in November 2015 and completed in May 2017. The company also carried out various trial studies with the same vaccine by using an adjuvant Matrix-M2 (It is human respiratory syncytial virus, derived from Quillaja saponins, cholesterol, and phosphatidylcholine). Therefore, robust pipeline is expected to propel global herpes simplex virus (HSV) vaccines market growth over the forecast period.

Moreover, according to the Centers for Disease Control and Prevention (CDC), in 2015, HSV-1 prevalence was 47.8%, while HSV-2 was 11.9% in the U.S.  According to the same source, linear increase in prevalence for both HSV-1 and HSV-2 in people aged within 14-19 is 27%, for population aged within 20–29 is 41%, and for the age ranging within 30–39 and 40–49 it is 54.1% and 59.7%, respectively. Furthermore, according to the World Health Organization (WHO), in 2017, around 3.7 billion people (67%) under age 50 years suffered from HSV-1 infection, and 417 million (11%) people aged 15-49 years suffered from HSV-2 infection, globally. This high rate of prevalence has created need for prevention and treatment of HSV, which is expected to drive global herpes simplex virus (HSV) vaccines market growth over the forecast period.

To understand Research Methodology, please click https://www.coherentmarketinsights.com/ongoing-insight/herpes-simplex-virus-hsv-vaccines-market-2845

Global Herpes Simplex Virus (HSV) Vaccines Market Regional Analysis

Extensive research and development activities in North America is expected to propel herpes simplex virus (HSV) vaccines market growth in the region during the forecast period. Several leading companies are focusing on research and development of herpes simplex virus (HSV) vaccines for prevention of it. For instance, GEN-003 of Genocea Biosciences, Inc. (based in the U.S.) has shown acceptable safety profile in phase III clinical trials in 2017, so it could be first upcoming vaccine available for HSV in the market boosting global herpes simplex virus (HSV) vaccines market growth.

According to the World Health Organization (WHO) regional infection prevalence estimates for HSV-1 among people range aged 0-49 years are 49% women and 39% men in U.S., 87% women and 87% men in Africa, 69% women and 61% men in Europe, and 74% women and 73% men in western pacific are found, while for HSV-2 are found to be highest in Africa (31.5%) than compared to the U.S. (14.4%). According to the same source, in many emerging economies, herpes simplex virus type-2 (HSV-2) infection is replacing chancroid and syphilis infections as a risk factor in development of genital ulcer diseases.

Global Herpes Simplex Virus (HSV) Vaccines Market Restraints

Though several companies are carrying out clinical trials for HSV vaccines, there is absence of a prophylactic and therapeutic vaccine in the market. However, few trails have shown promising results for prevention and treatment of HSV in clinical trials. Animal studies have shown potential results in clinical trials, however, different pathophysiology of the disease in animals and humans makes it difficult to produce the same results in human trials. For instance, clinical studies in mice and guinea pigs have produced more positive results than compared to human trials, as human HSV infection is different from that of animal HSV infection. These factors are expected to hamper global herpes simplex virus (HSV) vaccines market growth over the forecast period.

Global Herpes Simplex Virus (HSV) Vaccines Market Key Players

Some of the major players operating in the global herpes simplex virus (HSV) vaccines market include Sanofi S.A., GlaxoSmithKline Plc., Genocea Biosciences, Inc., Vical, Inc., and Others.

Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!

Get Discount For Buyers UPTO 30% OFF On Any Research Report
Apply Promo Code “CMIFIRST1000” And Get Instant Discount Of USD 1000
Buy Now this Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/2845

Global Herpes Simplex Virus (HSV) Vaccines market Taxonomy

By Vaccine:

• GEN-003
• VCL-HB01
• HSV529
• Others

By Indication:

• HSV-1 (Oral Herpes)
• HSV-2 (Genital Herpes)

By Region  

• North America
• Latin America
• Europe
• Asia Pacific
• Middle East
• Africa

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at contact@cdnnewswire.com.